Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00132652
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
- Conditions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00131742
2NN & CHARM Long-Term Follow-up Study
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2007-04-30
- Target Recruit Count
- 763
- Registration Number
- NCT00127972
- Locations
- 🇦🇺
Holdsworth House Medical Practice, Darlinghurst, Australia
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Avexa
- Target Recruit Count
- 52
- Registration Number
- NCT00126880
- Locations
- 🇦🇺
Avexa (co-ordinating sites in Australia and Argentina), Melbourne, Victoria, Australia
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
- Conditions
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00124241
Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2007-01-18
- Target Recruit Count
- 40
- Registration Number
- NCT00120783
- Locations
- 🇫🇷
Service de Medecine Interne hopital Avicenne, Bobigny, France
Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)
- Conditions
- Interventions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2016-07-21
- Target Recruit Count
- 8
- Registration Number
- NCT00120796
- Locations
- 🇸🇳
Hopital Principal, Dakar, Senegal
Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
- Conditions
- Interventions
- First Posted Date
- 2005-02-07
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 377
- Registration Number
- NCT00102960
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- Conditions
- First Posted Date
- 2005-01-26
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 6
- Registration Number
- NCT00102206
- Locations
- 🇺🇸
Columbia IMPAACT CRS, New York, New York, United States
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States
Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa
- Conditions
- Interventions
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00100646
- Locations
- 🇿🇦
University of the Witwatersrand, Johannesburg, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.